Development of New Strategy of Immunological Tolerance Inductionby Intraportal administration of donor specific Mesenchymal hepatic stem cell in OrganTransplantation

本研究旨在分析肝移植门静脉内给药诱导手术耐受的机制，提出肝干细胞诱导手术耐受的新方法。在基础检查中，慢性或急性肝炎患者肝脏中CD133+ NCAM+人肝/祖细胞在存在导管反应的区域周围被识别。尤其是在肝损伤程度较高的人肝脏中，其存在更为明显。然而，它在正常的人类肝脏中没有被识别出来。在门静脉内给予超级供体抗原的免疫学分析中，无免疫抑制剂的移植患者FoxP3^+/CD4^+CD25^+调节性T细胞数量增加。MELD评分20分以上患者细胞增多。结果表明，对移植患者术前免疫状况的掌握，有利于免疫抑制剂的使用。

The purpose of this study was to analyze the mechanisms of theinduction of operational tolerance in clinical liver transplantation by the intra-portaladministration of donor specific antigen and make the new method of induction of toleranceby hepatic stem cell. In the basic examination, the CD133+ NCAM+ human hepaticstem/progenitor cell was recognized around the region with existence of ductular reactionin the human liver with chronic or acute hepatitis. Especially, its existence was moreclearly in the human liver with higher hepatic injury. However, it was not recognizedin the normal human liver. In the immunological analysis of intra-portal administrationof super donor antigens, the population of FoxP3^+/CD4^+CD25^+ regulatory T cells increasedin the transplant patients with no immunosuppressants.Treg. cells increased in the patients above MELD score 20. It was proved that the graspof preoperative immunological situation of transplant patients take the betteradministration of immunosuppressants.